Drug Profile
Research programme: diabetes and metabolic disorder therapeutics - CASiGEN Pharma/Guangzhou Institute of Biomedicine and Health
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Guangzhou Institutes of Biomedicine and Health
- Developer CASiGEN Pharma; Guangzhou Institutes of Biomedicine and Health
- Class Small molecules
- Mechanism of Action ERRalpha estrogen-related receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in China (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in China (PO)
- 17 May 2012 Early research in Diabetes mellitus in China (PO)